Apixaban solid composition and preparation method thereof
The present invention provided an apixaban solid composition and a preparation method thereof. The method comprises granulating apixaban by wet granulation, wherein the apixaban has a particle size D 90 more than 89 μm.
1. An apixaban solid composition comprising apixaban having a particle size D 90 more than 89 μm, wherein the apixaban is dissolved in a wetting agent, wherein the wetting agent is an acidic substance or an organic solvent.
2. The apixaban solid composition of claim 1 , wherein the apixaban has a particle size D 90 between 100 μm and 550 μm.
3. The apixaban solid composition of claim 1 , wherein the apixaban solid composition further comprises a binder.
4. The apixaban solid composition of claim 3 , wherein the binder is povidone; or wherein the binder has a content of 2.00% to 8.00% by weight, based on the total weight of the apixaban solid composition.
5. The apixaban solid composition of claim 3 , wherein the binder is provided in dissolved form in an acidic substance or an organic solvent.
6. The apixaban solid composition of claim 3 further comprising a filler, a disintegrant, a surfactant and a lubricant.
7. The apixaban solid composition of claim 6 , wherein the filler is corn starch, pregelatinized starch, complex starch, lactose anhydrous, lactose monohydrate, microcrystalline cellulose, methylcellulose, hydroxy propyl cellulose, hydroxy propyl methyl cellulose, mannitol, maltitol, inositol, xylitol, lactitol or a combination thereof.
8. The apixaban solid composition of claim 6 , wherein the filler is a mixture of lactose anhydrous and microcrystalline cellulose, and wherein the content of the lactose anhydrous is from 33.50% to 63.50% and the content of the microcrystalline cellulose is from 24.00% to 54.00% by weight, based on the total weight of the apixaban solid composition.
9. The apixaban solid composition of claim 6 , wherein the disintegrant is croscarmellose sodium; or wherein the disintegrant is croscarmellose sodium having a content from 2.00% to 8.00% by weight, based on the total weight of the apixaban solid composition.
10. The apixaban solid composition of claim 6 , wherein the surfactant is sodium dodecyl sulfate; or wherein the surfactant is sodium dodecyl sulfate having a content from 0.50% to 4.00% by weight, based on the total weight of the apixaban solid composition.
11. The apixaban solid composition of claim 6 , wherein the lubricant is magnesium stearate; or wherein the lubricant is magnesium stearate having a content from 0.50% to 2.50% by weight, based on the total weight of the apixaban solid composition.
12. An apixaban solid composition comprising 2.50 parts by weight of apixaban, 33.50 to 63.50 parts by weight of lactose anhydrous, 24.00 to 54.00 parts by weight of microcrystalline cellulose, 2.00 to 8.00 parts by weight of croscarmellose sodium, 2.00 to 8.00 parts by weight of povidone, 0.50 to 4.00 parts by weight of sodium dodecyl sulfate and 0.50 to 2.50 parts by weight of magnesium stearate, wherein the apixaban has a particle size D90 more than 89 μm or between 100 μm and 550 μm, wherein the apixaban solid composition further comprises a wetting agent, and wherein the wetting agent is an acidic substance or an organic solvent.
13. The apixaban solid composition of claim 12 , wherein the apixaban solid composition comprises 2.50% of apixaban, 48.50% of lactose anhydrous, 39.00% of microcrystalline cellulose, 4.00% of croscarmellose sodium, 3.00% of povidone, 2.00% of sodium dodecyl sulfate and 1.00% of magnesium stearate by weight, based on the total weight of the apixaban solid composition, and wherein the apixaban has a particle size D 90 more than 89 μm; or
wherein the apixaban solid composition comprises 2.50% of apixaban, 63.50% of lactose anhydrous, 24.00% of microcrystalline cellulose, 4.00% of croscarmellose sodium, 3.00% of povidone, 2.00% of sodium dodecyl sulfate and 1.00% of magnesium stearate by weight, based on the total weight of the apixaban solid composition, and wherein the apixaban has a particle size D 90 more than 89 μm; or
wherein the apixaban solid composition comprises 2.50% of apixaban, 33.50% of lactose anhydrous, 54.00% of microcrystalline cellulose, 4.00% of croscarmellose sodium, 3.00% of povidone, 2.00% of sodium dodecyl sulfate and 1.00% of magnesium stearate by weight, based on the total weight of the apixaban solid composition, and wherein the apixaban has a particle size D 90 more than 89 μm; or
wherein the apixaban solid composition comprises 2.50% of apixaban, 47.50% of lactose anhydrous, 39.00% of microcrystalline cellulose, 2.00% of croscarmellose sodium, 8.00% of povidone, 0.50% of sodium dodecyl sulfate and 0.50% of magnesium stearate by weight, based on the total weight of the apixaban solid composition, and wherein the apixaban has a particle size D 90 more than 89 μm; or
wherein the apixaban solid composition comprises 2.50% of apixaban, 42.00% of lactose anhydrous, 39.00% of microcrystalline cellulose, 8.00% of croscarmellose sodium, 2.00% of povidone, 4.00% of sodium dodecyl sulfate and 2.50% of magnesium stearate by weight, based on the total weight of the apixaban solid composition, and wherein the apixaban has a particle size D 90 more than 89 μm.
14. A method of preparing an apixaban composition comprising:
granulating apixaban by using a wet granulation method, and dissolving apixaban in a wetting agent, wherein the wetting agent is an acidic substance or an organic solvent, and wherein the apixaban has a particle size D 90 more than 89 μm.
15. The method of claim 14 , wherein the wet granulation method comprises dissolving apixaban and a binder in the wetting agent to get a binder solution.
16. The method of claim 15 , wherein the binder is povidone; or wherein the content of the binder is from 0.02 g/mL to 0.5 g/mL in the wetting agent.
17. The method of claim 14 , wherein the particle size D 90 of the apixaban is between 100 μm and 550 μm.
18. The method of claim 15 further comprising:
preheating a filler, a disintegrant and a surfactant in a fluid-bed, wherein the temperature is from 35° C. to 50° C. after preheating;
spraying the binder solution to the preheated product, wherein the spraying is carried out under an atomizing pressure from 0.5 bar to 2.0 bar and at a spray speed from 3.0 g/min to 20.0 g/min;
drying the preheated product sprayed with the binder solution to get dry granules;
sizing the dry granules; and
blending a lubricant with the sized granules.
19. The method of claim 15 further comprising:
pre-blending a filler, a disintegrant and a surfactant in a high shear wet granulator;
spraying the binder solution to the pre-blended product to get wet granules, wherein the spraying is carried out at a spraying speed from 5 g/min to 60 g/min;
drying the wet granules in a fluid-bed to get dry granules;
sizing the dry granules; and
blending a lubricant with the sized granules.
20. The method of claim 14 further comprising compressing the blend product into tablets and coating the tablets.
21. The apixaban solid composition of claim 1 , wherein the apixaban solid composition is obtained by using a wet granulation method.
22. The apixaban solid composition of claim 1 , wherein the apixaban solid composition is in a form of immediate release tablets.
23. The apixaban solid composition of claim 1 , wherein the acidic substance is formic acid, acetic acid, a combination thereof, or a mixture thereof with water; wherein the organic solvent is DMSO a combination thereof, or a mixture thereof with water.
24. The apixaban solid composition of claim 5 , wherein the acidic substance is acetic acid; or wherein the content of the binder is from 0.02 g/mL to 0.5 g/mL in acetic acid.